Yüklüyor......
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant...
Kaydedildi:
| Yayımlandı: | Therap Adv Gastroenterol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4913332/ https://ncbi.nlm.nih.gov/pubmed/27366220 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16638833 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|